APA (7th ed.) Citation

HX, N., AY, X., GE, V., N, Z., VK, C., EV, K., . . . RM, S. (2024). Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 78(6), 1680. https://doi.org/10.1093/cid/ciae119

Chicago Style (17th ed.) Citation

HX, Ngo, et al. "Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America 78, no. 6 (2024): 1680. https://doi.org/10.1093/cid/ciae119.

MLA (9th ed.) Citation

HX, Ngo, et al. "Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis." Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America, vol. 78, no. 6, 2024, p. 1680, https://doi.org/10.1093/cid/ciae119.